Patent US4294826A successfully refreshed from Google Patents.
US4294826A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Process for the preparation of highly purified antihemophilic factor
Assignee: Armour Pharmaceutical Co
•
Filing: 1980-05-07
•
Granted: 1981-10-13
•
Expires: 2000-05-07
Abstract
Abstract An antihemophilic factor derived from human blood plasma, having about 1 to 10 units antihemophilic factor activity per mg of protein and being substantially free of denatured antihemophilic factor is prepared from material having 0.3 to 1.0 unit per mg of protein.
Inventors
- 👤 Fred Feldman
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-03 15:19
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/745; C07K14/755; A; A61; A61K; A61K38/00; Y; Y10; Y10S; Y10S530/00; Y10S530/806; Y10S530/827; Y10S530/829; Y10S530/83
Claims Analysis
Total Claims: 7
Claim 1
Independent Claim
153 words
A process for the preparation of an aqueous composition of antihemophilic factor having a concentration of about 20 to 45 units of antihemophilic factor per ml, a specific antihemophilic factor activity of at least 1 unit per mg protein, and being obtained from an aqueous solution of antihemophilic factor derived from human blood plasma, said aqueous solution having a concentration of about 5 to 15 units of antihemophilic factor per ml, and a specific antihemophilic factor activity of about 0.3 to 1.0 unit per mg protein, which comprises: (a) effecting about a 2- to 10-fold concentration of the low concentrate solution, (b) adjusting the pH of said concentrated solution to about 5.0 to 6.0, (c) cooling the resultant solution to about 0 ° to 14° C., (d) removing the precipitate which forms at said pH and temperature, (e) further clarifying the solution from step (d), and (f) adjusting the pH to about 7.0.
Claim 2
Dependent Claim
153 words
A process for the preparation of an aqueous composition of antihemophilic factor having a concentration of about 20 to 45 units of antihemophilic factor per ml, a specific antihemophilic factor activity of at least 1 unit per mg protein, and being obtained from an aqueous solution of antihemophilic factor derived from human blood plasma, said aqueous solution having a concentration of about 5 to 15 units of antihemophilic factor per ml, and a specific antihemophilic factor activity of about 0.3 to 1.0 unit per mg protein, which comprises: (a) effecting about a 2- to 10-fold concentration of the low concentrate solution, (b) adjusting the pH of said concentrated solution to about 5.0 to 6.0, (c) cooling the resultant solution to about 0 ° to 14° C., (d) removing the precipitate which forms at said pH and temperature, (e) further clarifying the solution from step (d), and (f) adjusting the pH to about 7.0.
Claim 3
Dependent Claim
52 words
An aqueous composition of antihemophilic factor derived from human blood plasma, said composition having a cencentration of 20 to 45 units of antihemophilic factor per ml, said antihemophilic factor having a specific antihemophilic factor activity of at least 1 unit per mg protein, when prepared by a process according to claim 1.
Claim 4
Dependent Claim
46 words
A freeze-dried composition of antihemophilic factor derived from human blood plasma, having about 1 to 10 units antihemophilic factor activity per mg protein with a ratio of antigenic Factor VIII to Factor VIII procoagulant activity of approximately one and being substantially free of denatured antihemophilic factor.
Claim 5
Dependent Claim
46 words
A freeze-dried composition of antihemophilic factor derived from human blood plasma, having about 1 to 10 units antihemophilic factor activity per mg protein with a ratio of antigenic Factor VIII to Factor VIII procoagulant activity of approximately one and being substantially free of denatured antihemophilic factor.
Claim 6
Dependent Claim
59 words
An aqueous composition of antihemophilic factor derived from human blood plasma, having a concentration of about 20 to 45 units antihemophilic factor activity per ml and at least 1 unit antihemophilic factor activity per mg protein, with a ratio of antigenic Factor VIII to Factor VIII procoagulant activity of approximately one and being substantially free of denatured antihemophilic factor.
Claim 7
Dependent Claim
59 words
An aqueous composition of antihemophilic factor derived from human blood plasma, having a concentration of about 20 to 45 units antihemophilic factor activity per ml and at least 1 unit antihemophilic factor activity per mg protein, with a ratio of antigenic Factor VIII to Factor VIII procoagulant activity of approximately one and being substantially free of denatured antihemophilic factor.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1984-10-12 | 1985-04-13 | 1985-10-13 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1988-10-12 | 1989-04-13 | 1989-10-13 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1992-10-12 | 1993-04-13 | 1993-10-13 | $7700.00 | Window Closed / Lapsed |